Dizal Pharma. [Photo/WeChat account: xinwu_wx]

Dizal Pharma, a pioneering biopharmaceutical company based in Wuxi National Hi-Tech District, announced on June 19 that its independently developed drug golidocitinib had been officially approved by China's National Medical Products Administration. Golidocitinib marks a major milestone for the global health industry, as it is the world's first selective JAK1 inhibitor for the treatment of peripheral T-cell lymphoma (PTCL).

PTCL is known for its high malignancy and complex pathogenesis, posing a significant challenge to the global pharmaceutical industry. For the past decade, no innovative drugs have been introduced to treat the disease. Dizal Pharma's groundbreaking approach, utilizing a unique molecular structure to achieve high selectivity for JAK1, has led to the development of golidocitinib.

Zhang Xiaolin, CEO of Dizal Pharma, said that the company will advance the process of overseas registration to ensure that this novel treatment can benefit patients worldwide as quickly as possible.

Since its founding six years ago, Dizal Pharma has focused on the research, development, and commercialization of innovative therapies for malignant tumors and immune diseases. The company has launched two groundbreaking drugs and is currently working to include these products in China's national medical insurance catalog to enhance patient accessibility.

A researcher at Dizal Pharma. [Photo/WeChat account: xinwu_wx]

Biopharmaceuticals are a key strategic emerging industry for Wuxi National Hi-Tech District. In 2023, the industry maintained double-digit growth, with its scale surpassing 100 billion yuan ($13.77 billion), accounting for 52.3 percent of the city's total. The district is now home to 620 biopharmaceutical companies.